Shionogi Completes Acquisition of Drug Rights for RADICAVA

On April 1, 2026, the pharmaceutical company Shionogi & Co., Ltd. finalized a major deal, acquiring the global rights to the ALS treatment RADICAVA from Tanabe Pharma Corporation for $2.5 billion.

RADICAVA, known by the generic name edaravone, is a vital therapy for patients living with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative condition.

This acquisition is expected to bolster Shionogi’s annual sales by approximately $700 million while helping them develop future treatments for other rare conditions like Pompe disease.

This deal highlights a broader trend within the Japanese pharmaceutical industry, where companies are increasingly refocusing their business models on specialized high-impact therapeutic areas to address significant unmet medical needs.